Hepatitis C patients have been protesting for past one week outside India’s patent office in Dwarka against Gilead Sciences and the United States government for forcing the Indian government “to blindly and speedily grant patents”. IPO is in the process of hearing the company’s patent claim on the drug Sovaldi, with an astounding price of $84,000 (about Rs.57 lakh) in the U.S [more].
Comments